{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:03:09Z","timestamp":1789984989651,"version":"4.0.1"},"reference-count":37,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Ulcerative colitis (UC) remains difficult to control in a substantial proportion of patients despite an expanding range of advanced therapies. Interleukin-7 (IL-7) is a homeostatic cytokine that supports lymphocyte survival, persistence and intestinal trafficking through signalling via IL-7 receptor-\u03b1 (IL-7R\u03b1; CD127), providing a rationale for selective pathway inhibition in chronic intestinal inflammation. This narrative review examines the biology of IL-7\/IL-7R signalling in inflammatory bowel disease (IBD) and summarises the preclinical, translational and clinical development of lusvertikimab, a humanised monoclonal antibody targeting IL-7R\u03b1. MEDLINE was searched from inception to 31 July 2026, supplemented by reference-list screening, trial registries, conference proceedings and regulatory sources. Experimental studies show that IL-7 supports the persistence of colitogenic effector-memory T cells and contributes to innate immune activation. Human translational data demonstrate enrichment of IL-7R pathway activity in treatment-refractory IBD, association with anti-TNF non-response, and IL-7-mediated upregulation of the gut-homing integrin \u03b14\u03b27. Preclinical IL-7R blockade attenuated experimental colitis, reduced intestinal T-cell trafficking and altered inflammatory responses in UC tissue. In a first-in-human study, lusvertikimab produced sustained receptor occupancy and suppression of IL-7-associated gene expression without broad lymphocyte depletion. In the phase II CoTikiS trial, lusvertikimab improved Modified Mayo Score versus placebo, with significant pooled endoscopic improvement but no significant pooled differences in clinical or endoscopic remission. Early safety findings were reassuring. Selective IL-7R\u03b1 blockade therefore represents a biologically distinct therapeutic strategy in UC, although larger controlled studies, biomarker validation and clarification of dose selection and long-term safety are required to define its clinical role and whether combination strategies warrant future evaluation in selected patients.<\/jats:p>","DOI":"10.3390\/life16091572","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:38Z","timestamp":1789981298000},"page":"1572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Interleukin-7 Signalling in Ulcerative Colitis: Rationale and Emerging Clinical Evidence"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-9086","authenticated-orcid":false,"given":"Magdalini","family":"Manti","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, St Mark\u2019s The National Bowel Hospital, London NW10 7NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Raspa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust, London SW17 0QT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust, London SW17 0QT, UK"},{"name":"Infection and Immunity Research Institute, City St George\u2019s, University of London, Cranmer Terrace, London SW17 0RE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-2763","authenticated-orcid":false,"given":"Sailish","family":"Honap","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust, London SW17 0QT, UK"},{"name":"Infection and Immunity Research Institute, City St George\u2019s, University of London, Cranmer Terrace, London SW17 0RE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Berre","year":"2023","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41573-024-00953-0","article-title":"Navigating the complexities of drug development for inflammatory bowel disease","volume":"23","author":"Honap","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"156049","DOI":"10.1016\/j.cyto.2022.156049","article-title":"IL-7: Comprehensive review","volume":"160","author":"Winer","year":"2022","journal-title":"Cytokine"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chen, D., Tang, T.-X., Deng, H., Yang, X.-P., and Tang, Z.-H. (2021). Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.747324"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1172\/JCI121668","article-title":"IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease","volume":"129","author":"Belarif","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood-2012-06-434779","article-title":"IL-7 induces expression and activation of integrin \u03b14\u03b27 promoting naive T-cell homing to the intestinal mucosa","volume":"120","author":"Cimbro","year":"2012","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"i143","DOI":"10.1093\/ecco-jcc\/jjae190.0070","article-title":"DOP031 Anti-IL-7 receptor plus anti-IL12\/23 combination induces complete histological normalization in chronic colitis","volume":"19","author":"Lyssia","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_9","unstructured":"(2026, August 17). Lusvertikimab (OSE-127). Ose Immunotherapeutics\u2014Soci\u00e9t\u00e9 de Biotechnologie Int\u00e9gr\u00e9e Qui D\u00e9veloppe des Immunoth\u00e9rapies Innovantes. Available online: https:\/\/www.ose-immuno.com\/en\/our-products\/ose-127-modular\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4049\/jimmunol.2200635","article-title":"First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7R\u03b1","volume":"210","author":"Poirier","year":"2023","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"i71","DOI":"10.1093\/ecco-jcc\/jjae190.0036","article-title":"OP36 Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe Ulcerative Colitis: Results of a multicenter, randomized, placebo-controlled phase II study","volume":"19","author":"Bourreille","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1172\/JCI118002","article-title":"Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes","volume":"95","author":"Watanabe","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Markovi\u0107, I., and Savvides, S.N. (2020). Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01557"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1128\/MCB.24.14.6501-6513.2004","article-title":"Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members","volume":"24","author":"Jiang","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2567.2009.03244.x","article-title":"Interleukin-7 promotes the survival of human CD4+ effector\/memory T cells by up-regulating Bcl-2 proteins and activating the JAK\/STAT signalling pathway","volume":"130","author":"Chetoui","year":"2010","journal-title":"Immunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1359-6101(98)00025-2","article-title":"Interleukin-7: Physiological roles and mechanisms of action","volume":"10","author":"Hofmeister","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ng.764","article-title":"Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47","volume":"43","author":"Anderson","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.187.3.389","article-title":"Interleukin 7 Transgenic Mice Develop Chronic Colitis with Decreased Interleukin 7 Protein Accumulation in the Colonic Mucosa","volume":"187","author":"Watanabe","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.4049\/jimmunol.178.8.4737","article-title":"IL-7 Is essential for the development and the persistence of chronic colitis","volume":"178","author":"Totsuka","year":"2007","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.4049\/jimmunol.171.3.1556","article-title":"Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis","volume":"171","author":"Yamazaki","year":"2003","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.1000057","article-title":"Upregulated IL-7 receptor \u03b1 expression on colitogenic memory CD4+ T cells may participate in the development and persistence of chronic colitis","volume":"186","author":"Shinohara","year":"2011","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.immuni.2012.09.008","article-title":"The Transcription Factor T-bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid Cells","volume":"37","author":"Powell","year":"2012","journal-title":"Immunity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.cgh.2020.02.010","article-title":"Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Shalapour, S., Deiser, K., K\u00fchl, A.A., Glauben, R., Krug, S.M., Fischer, A., Ser-can, \u00d6., Chappaz, S., Bereswill, S., and Heimesaat, M.M. (2012). Interleukin-7 Links T Lymphocyte and Intestinal Epithelial Cell Homeostasis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031939"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1476-9255-9-39","article-title":"Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis","volume":"9","author":"Willis","year":"2012","journal-title":"J. Inflamm."},{"key":"ref_27","unstructured":"World Health Organisation (2021). WHO Drug Information\u2014Recommended INN: List 86\u2014International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organisation."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ibd\/izaf334","article-title":"Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology","volume":"32","author":"Colwill","year":"2026","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2021-150323","article-title":"IL7R Targeting Using OSE-127 Shows Robust Anti-Leukemic Activity in B-Cell Precursor Acute Lymphoblastic Leukemia Xenografts","volume":"138","author":"Lenk","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1038\/s41467-018-06804-y","article-title":"IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates","volume":"9","author":"Belarif","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_31","unstructured":"OSE Immunotherapeutics (2026). Randomized, Double-Blind, Phase 2 Study to Evaluate the Efficacy and the Safety of OSE-127 Versus Placebo in Subjects with Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Previous Treatment(s)."},{"key":"ref_32","unstructured":"OSE Immunotherapeutics (2025). OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab, OSE Immunotherapeutics."},{"key":"ref_33","unstructured":"OSE Immunotherapeutics (2025). OSE Immunotherapeutics Unveils 2026\u20132028 Strategic Plan with Four Opportunities for Value Creation, OSE Immunotherapeutics."},{"key":"ref_34","unstructured":"OSE Immunotherapeutics (2026). OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab, OSE Immunotherapeutics."},{"key":"ref_35","unstructured":"European Medicines Agency (EMA) (2024). EU\/3\/23\/2802\u2014Orphan Designation for Treatment of Acute Lymphoblastic Leukaemia, European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-23-2802."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/annrheumdis-2024-eular.829","article-title":"POS0375 Assessment of S95011 (ose-127, Lusvertikimab), an Anti-Interleukin 7 Receptor Monoclonal Antibody, in Patients with Primary Sj\u00f6gren\u2019s Syndrome: An International Multicentre, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study","volume":"83","author":"Fisher","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.17294\/2330-0698.1722","article-title":"The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis","volume":"7","author":"Yarlas","year":"2020","journal-title":"J. Patient-Centered Res. Rev."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:31:37Z","timestamp":1789983097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091572"],"URL":"https:\/\/doi.org\/10.3390\/life16091572","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}